Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies

Completed

Conditions studied: Leukemia, Lymphoma

In brief

The purpose of this project is to assess the efficacy of loratadine in decreasing the incidence and severity of bone pain following G-CSF administration in patients with hematologic malignancies, patients undergoing mobilization of hematopoietic progenitor cells, and patients who have undergone an autologous hematopoietic cell transplant. This is a different patient population than those being assessed in current clinical trials.

Key facts

Study ID

NCT02305979

Run by

Wake Forest University Health Sciences

People needed

61

Starts

2014-12-01

Expected to finish

2017-09-01

Last updated by the study team

2018-07-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Receiving a G-CSF after the institution practice change
• Receiving a G-CSF for one of the following indications:
• Prevention/treatment of neutropenia along with treatment for leukemia or lymphoma
• Mobilization of hematopoietic progenitor cells
• Neutropenia prevention following autologous hematopoietic cell transplant
• Took loratadine per protocol with G-CSF administration
• Completed a survey

You may not qualify if…

• Taking daily antihistamines for allergies, asthma, or other indications, not including bone pain
• Taking daily NSAIDs, with the exception of aspirin, for chronic conditions
• Treatment for solid tumor cancers
• Receiving bone modifying agents for bone pain associated with metastatic disease or other chronic conditions

Where it is running

• Comprehensive Cancer Center of Wake Forest University — Winston-Salem, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.